Katherine West is a Senior Lecturer in Molecular Biosciences at the University of Glasgow. Her research focuses on chromatin-binding proteins, particularly the HMGN family, and their roles in DNA repair, gene expression, and stem cell biology. She has contributed to advancements in CRISPR-Cas9 technology, epigenetic regulation of pluripotency, and cancer-related education methodologies. Key Research Themes: Epigenetic mechanisms in stem cell differentiation HMGN protein function in chromatin dynamics CRISPR-Cas9 optimization for transgene integration Interdisciplinary medical education innovations Grant History: Research funded by Tenovus Scotland, BBSRC, AICR, and European Commission for projects spanning DNA repair, HMGN protein engineering, and cancer therapy sensitization.
Sumana Sharma is a Wellcome Career Development Fellow and Group Leader at the MRC Weatherall Institute of Molecular Medicine (University of Oxford). Her research focuses on T-cell signaling and next-generation immunotherapy design , particularly through inhibitory receptor signaling manipulation . PhD in genetic screening (Wellcome Sanger Institute, University of Cambridge) Postdoc in computational analysis (EMBL-EBI, Cambridge) Former Sir Henry Wellcome Postdoctoral Fellow (MRC-TIDU, Oxford) Her work integrates CRISPR-based functional genomics , omics technologies , and primary T-cell editing to uncover regulatory mechanisms in immune suppression. Key contributions include developing CEN-tools for cancer gene analysis and creating high-throughput assays for T-cell signaling. Recent publications span 2025-2015 , emphasizing T-cell antigen detection , inhibitory signaling , and transcriptional reprogramming . Her research trends combine structural immunology , computational genomics , and therapeutic engineering . Wellcome Career Development Award Sir Henry Wellcome Postdoctoral Fellowship Her lab uses multidisciplinary approaches to study immune regulation in cancer and chronic infections , with potential applications in autoimmune disease and tumor immunotherapy .
Richard Salisbury is a CRUK Clinical Research Training Fellow at the University of Oxford, affiliated with Hertford College. His research focuses on molecular mechanisms in haematological malignancies, particularly Chronic Myelomonocytic Leukaemia (CMML). His core research interests include: Haematology Oncology Epigenetics Cancer Research Stem Cell Biology Molecular Biology Salisbury investigates TET2 loss-of-function mutations (present in 60% of CMML patients) using multiomic single-cell profiling. His work demonstrates that TET2-mutant haematopoietic stem and progenitor cells (HSPCs) are epigenetically reprogrammed to hijack emergency myelopoiesis pathways, causing hypersensitivity to bone marrow niche cytokines like M-CSF. Current research aims to identify druggable pathways for novel anti-cancer therapies in CMML. No scientific awards were mentioned in the source material. No information regarding student advising or research grants was provided in the available text.
Noah Freeman Shroyer, Ph.D. is an Associate Professor in the Department of Medicine, Section of Gastroenterology and Hepatology at Baylor College of Medicine in Houston, Texas. He also holds an Adjunct Associate Professor position in the Department of Pediatrics Division of Gastroenterology, Hepatology & Nutrition at Cincinnati Children's Hospital, University of Cincinnati. Additionally, he is a Member of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and serves as Core Director of the Digestive Diseases Center at Texas Medical Center. Education: BS in Microbiology and Biochemistry from Louisiana State University, Baton Rouge PhD in Cell and Molecular Biology from Baylor College of Medicine, Houston Post-Doctoral Fellowship in Molecular and Human Genetics at Baylor College of Medicine, Houston Dr. Shroyer's research primarily focuses on understanding the mechanisms that control intestinal development and homeostasis, with particular emphasis on epithelial transcription factors such as Atoh1 (Math1), Gfi1, and Spdef. His laboratory has made significant contributions to understanding how these factors regulate intestinal development and differentiation, and how their dysfunction relates to diseases like inflammatory bowel disease and colorectal cancer. He has pioneered the development of organ culture methods to direct differentiation of human pluripotent stem cells into intestinal tissue, creating valuable models for studying intestinal development, disease mechanisms, and potential therapeutic approaches. Analysis of Dr. Shroyer's recent publications (2022-2025) reveals a strong focus on intestinal organoid models, vitamin D signaling in the gut, stem cell biology, and colorectal cancer mechanisms. His work increasingly integrates enteric nervous system components with intestinal epithelium in organoid models, examines sex differences in intestinal biology, and explores metabolic pathways in intestinal stem cells and cancer. The research demonstrates a progression from basic developmental mechanisms toward more translational applications, including therapeutic targeting of pathways like Wnt/β-catenin and metabolic regulators in colorectal cancer. Dr. Shroyer's laboratory has established itself as a leader in intestinal stem cell and organoid research, with significant contributions to understanding transcriptional regulation in intestinal development and disease. His work bridges basic science with clinical applications, particularly in the areas of colorectal cancer and intestinal regeneration. While specific grant information is not detailed in the provided text, Dr. Shroyer's extensive publication record spanning from 1997 to the present suggests sustained research funding. His work likely involves collaborations across multiple institutions, including Baylor College of Medicine, Cincinnati Children's Hospital, and other research centers focused on gastrointestinal diseases and cancer. His laboratory appears to focus on both fundamental developmental biology questions and translational applications for gastrointestinal diseases. Dr. Shroyer's laboratory maintains a strong focus on developing and utilizing human intestinal organoid models to study development, disease mechanisms, and potential therapeutic interventions. The lab's work with human pluripotent stem cell-derived intestinal tissue represents a cutting-edge approach to modeling human intestinal biology and disease in vitro.
Dr. Simon Maksour serves as the Race Against Dementia – Dementia Australia Research Foundation Research Fellow (2025-2030) within the School of Medical Sciences at the University of Sydney's Faculty of Medicine and Health. His research bridges molecular neuroscience and therapeutic development for neurodegenerative disorders. Dr. Maksour's research focuses on modeling neurodegenerative diseases using induced pluripotent stem cells (iPSCs) to generate neural cells and organoids. His work spans Alzheimer's disease , Motor Neuron Disease , Friedreich's ataxia , Vanishing White Matter disease , Huntington's disease , and Parkinson's disease . Current projects target microglia-specific therapies for Alzheimer's disease, including gene therapy validation in advanced stem cell models and microglial cell replacement strategies. His publication record demonstrates consistent output in high-impact journals, with recent first-author papers in BMC Biology (2025), Frontiers in Cellular Neuroscience (2024), and Antioxidants & Redox Signaling (2024). Research themes include: Neurosciences and Mental Health Healthy Ageing Cellular/Molecular mechanisms of neurodegeneration Therapeutic interventions for dementia Dr. Maksour received the Australasian Society for Stem Cell Research (ASSCR) Rising Star Award for his contributions to stem cell modeling of neurodegenerative conditions. His work has been featured in media outlets including 2GB Sydney and UOW communications. As an active supervisor, he offers PhD and honours projects in microglia-targeted Alzheimer's therapies, microglial replacement strategies, and neuroprotective compound screening using brain organoids. His Race Against Dementia Fellowship provides dedicated funding through 2030 for developing novel therapeutic approaches.
Irina V Balyasnikova is a Professor in the Department of Neurological Surgery at Northwestern University's Feinberg School of Medicine, specializing in novel targeted therapies for malignant brain tumors through antibody engineering and stem cell-based approaches. Education: MS: Ivanovo State University (1987) PhD: National Cardiology Research Center, Moscow, Russia (1994) Postdoctoral Fellow: University of Pennsylvania, Institute for Environmental Medicine (1997) Postdoctoral Fellow: University of Illinois, Chicago, Anesthesiology (2000) Research Focus: Dr. Balyasnikova pioneers antibody-based therapeutics against tumor-specific antigens and stem cell carrier systems for brain tumor treatment. Her work integrates molecular imaging for non-invasive tracking and investigates migration mechanisms of therapeutic stem cells to solid tumors and metastases, with strong emphasis on glioblastoma immunotherapy and nanomedicine delivery systems . Publication Trends: Her 2024-2025 publications reveal intensive focus on glioblastoma heterogeneity solutions (CAR T-cells, tri-specific engagers), immune microenvironment reprogramming (STING agonists), nanomedicine barriers, and CNS autoimmune triggers. These works demonstrate interdisciplinary convergence of oncology, immunology, and biomedical engineering with translational emphasis. Scientific Recognition: 2024 Ryan Accelerator Research Fund for Tri-Specific T-cell Engagers 2024 Chicago Biomedical Consortium Accelerator Award 2024 Charlie Teo Brain Tumor Foundation grant (Australia) H Foundation Core Usage Award (2021) Multiple Translational Bridge Program awards (2017) Charles B. Huggins Research Symposium Faculty Awards (2013, 2015) Professional Leadership: Dr. Balyasnikova serves as Co-chair for Gordon Research Conference: Biotherapeutics and Vaccines Development (2024) and maintains active membership in AACR (2018-present), WMIS (2016-present), SNO (2011-present), and ASGCT (2010-present). Her grant portfolio includes continuous NIH/NCI funding through RHLCCC and institutional awards supporting her translational neuro-oncology work. Research Infrastructure: She operates within the Robert H. Lurie Comprehensive Cancer Center ecosystem, leveraging Skin Biology and Diseases Resource-Based Center resources for molecular imaging and therapeutic development, with recent work featured in Northwestern Medicine's glioblastoma breakthrough announcements.
Håkan Toresson is an Associate Professor affiliated with Lund University , specializing in Cognitive Disorders . His research bridges Neuroscience and Healthcare Economics , focusing on Alzheimer's Disease , Dementia , and cost-effectiveness of interventions. Active researcher in Swedish BioFINDER Study (2010–2027) Principal Investigator in Medication Review for Dementia (2023–2027) Research Themes : Neuron differentiation via fibroblast conversion Healthcare cost analysis for dementia progression Economic modeling of screening and management protocols Systematic reviews of nonpharmacological interventions Swedish register-based longitudinal studies Public health policy for neurodegenerative diseases Collaborations : Engaged with Hjärnfonden , Alzheimerfonden , MultiPark , and European Commission .
Zhongjian Cheng, PhD, is an Assistant Professor in the Department of Cardiovascular Sciences at Temple University's Lewis Katz School of Medicine. His research focuses on diabetes-mediated cardiovascular complications, particularly the mechanisms of vascular injury, endothelial dysfunction, and myocardial repair. He investigates extracellular vesicles/exosomes from diabetic cells and their modification via genetic, epigenetic, and metabolite approaches to enhance regenerative properties. Education: PhD from University of Helsinki; Postdoctoral fellowship at University of Calgary Affiliation: Member of the Aging + Cardiovascular Discovery Center Dr. Cheng's work spans diabetic cardiovascular complications , extracellular vesicle biology , epigenetic modifications , and non-coding RNA (circular RNA, miRNA). His studies use animal models to explore vascular relaxation impairments , myocardial infarction , and heart failure mechanisms. His recent publications highlight exosome-based therapeutics for heart failure, epigenetic sex differences in cardiac repair, and circRNA/miRNA roles in macrophage and endothelial cell function. Key awards include multiple American Heart Association grants .
Amy Wagers, Ph.D. , is the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University. She serves as Chair of the Harvard Stem Cell Institute (HSCRB), a Harvard College Professor , and holds affiliations with the Joslin Diabetes Center (Senior Investigator) and the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. Harvard University, Ph.D. in Immunology and Microbial Pathogenesis (1999), Northwestern University Postdoctoral Fellowship, Stanford University School of Medicine (1999-2004), under Dr. Irving Weissman Dr. Wagers' research defines intrinsic and extrinsic regulators of adult blood-forming and muscle-forming stem cells, focusing on their roles in injury repair, degenerative diseases, and malignancy. Her lab pioneered in vivo gene-editing methods using adeno-associated virus (AAV) to target congenital and age-related diseases like Duchenne muscular dystrophy and spinal muscular atrophy. Key findings include blood-borne mediators , cellular niches, and inflammatory/metabolic cues that coordinate stem cell functions throughout the body. Her publications (over 150) emphasize age-associated stem cell decline and interventions to reverse age-related dysfunction. Notable articles include 2016 Science and Circulation Research studies on GDF11 and AAV-based gene editing, and a 2019 Cell Reports paper on in situ genome modification. Scientific Awards: 2018 NIH Pioneer Award Burroughs Wellcome Fund Career Award in Biomedical Sciences Smith Family New Investigator Award Keck Foundation Young Scholars Award Dr. Wagers' lab includes current and former members such as David Anderson (gene therapy for blood disorders), Heyuan Qin (immunology and aging), and Eric Gähwiler (Masters thesis on hematopoietic stem cells). Her team explores cellular reprogramming , marker-based cell sorting, and AAV delivery systems to enhance stem cell therapies.
Gregory Verdine is the Erving Professor of Chemistry at Harvard University, with primary appointments in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology. He is a pioneering figure in chemical biology, DNA repair mechanisms, and therapeutic modality development, particularly known for inventing stapled peptides that target previously "undruggable" proteins. Verdine also serves as Chairman of the Board of Directors at WaVe Life Sciences and President/CEO of FogPharma, while maintaining advisory roles at institutions like Memorial Sloan-Kettering Research Institute and National Cancer Institute. Harvard University (Stem Cell and Regenerative Biology, Chemistry and Chemical Biology) Founder/Co-Founder of 8 biotech companies (Enanta, Gloucester, Tokai, WaVe, Eleven Biotherapeutics, Warp Drive Bio, Aileron, FogPharma) Non-Profit Leadership: Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy Research focuses on chemical biology and genomic stability , with key discoveries in: Molecular mechanisms of epigenetic DNA methylation Genotoxic DNA damage surveillance pathways Design of stapled peptides for protein-protein interaction modulation Applications in oncology (β-catenin, Ras, RAB25 targeting) Advancing nucleotide excision repair systems Antisense oligonucleotide stereochemical optimization His 15 most recent publications (2013-2024) reveal trends in: Covalent enzyme inhibitors Genomic modality discovery Ubiquitin ligase reprogramming Protein structure remodelling Allele-selective genetic therapies DNA lesion recognition mechanisms Awards include the 2024 AACR Award for Excellence in Chemistry in Cancer Research and Nobel Laureate Signature Award . He has translated academic research into clinical applications through multiple FDA-approved drugs (romidepsin, paritaprevir) and currently leads FogPharma's Cell-Penetrating Miniprotein platform. Academic collaborators span Harvard, MIT, and major biomedical research institutions.
Richard Maas is a Professor at Harvard Medical School affiliated with Brigham and Women's Hospital, leading the Maas Laboratory focused on vertebrate organ development and regeneration. His research spans two primary areas: (1) Systems-based Consortium for Organ Design and Engineering (SysCODE), a $24M NIH-funded initiative for stem cell-based organ regeneration, and (2) mechanistic studies of Pax6 , Hox , and related genes in eye, craniofacial, pancreatic, and kidney development. Key affiliations: Brigham and Women's Hospital, Harvard Medical School, NIH SysCODE Consortium Research domains: Developmental genetics, gene networks, interdisciplinary regenerative medicine His lab employs experimental embryology, molecular genetics, and computational approaches to unravel evolutionary conserved pathways in organogenesis, with applications to human birth defects. Current projects include regenerating tooth germ, pancreatic islets, and heart valves through multidisciplinary collaboration. Scientific contributions include: Establishing causal roles of genes like ROBO2 , NFIA , and SUMO1 in renal and craniofacial defects Developing iSyTE computational platform for eye gene discovery Characterizing molecular blueprints for tissue engineering through genomic/proteomic integration The lab actively trains students and postdocs through NIH-funded interdisciplinary programs, with a focus on bridging developmental biology and bioengineering.
Fernando Camargo, Ph.D. , is a Professor of Stem Cell and Regenerative Biology at Harvard University and a Principal Faculty member of the Harvard Stem Cell Institute . His lab is based at Children’s Hospital Boston , where he investigates fundamental mechanisms of adult stem cell biology , organ size regulation , and cancer pathogenesis . Education: Ph.D., Baylor College of Medicine (2004) Prior Positions: Whitehead Fellow, Whitehead Institute for Biomedical Research (2004-2009) Research Interests include: YAP/TAZ signaling in organ growth and regeneration Single-cell lineage tracing to map hematopoietic and intestinal stem cell dynamics Epigenetic barriers to cellular reprogramming Mechanotransduction in intestinal stem cells Crosstalk between Hippo and metabolic pathways (e.g., glutamine/nucleotide synthesis) Stem cell aging and tumor suppression via transcriptional regulators Recent Articles reveal expertise in: 2025: Epigenetic regulation in liver reprogramming 2023: Multimodal single-cell profiling and mechanotransduction in gut stem cells 2022: Aging-dependent transcriptional control in hematopoiesis 2020: In vivo stem cell imaging and Hippo-metabolism integration 2018: Hippo pathway genomic analysis in cancer Scientific Awards: 2009 V Foundation Scholar NIH Director’s New Innovator Award Lab Members include researchers developing innovative technologies for live-cell imaging and CRISPR-based lineage tracing , with clinical translation efforts in bone marrow transplantation and liver disease therapies.
Ya-Chieh Hsu is Professor of Stem Cell and Regenerative Biology at Harvard University, a Principal Faculty Member at the Harvard Stem Cell Institute, and an associate member of the Broad Institute. She leads the Hsu Laboratory, which focuses on understanding the principles and molecular nature of cell-cell interactions governing development, regeneration, and injury repair using mammalian skin as a model system. Dr. Hsu completed her Ph.D. at Baylor College of Medicine, where she studied pathways controlling organ size using Drosophila as a model. For her postdoctoral research, she worked in Elaine Fuchs' laboratory at the Rockefeller University, where she delineated the lineage hierarchy of hair follicle cells and investigated how signals from stem cell progeny regulate hair follicle stem cells. Dr. Hsu's research centers on stem cell biology with particular emphasis on transit-amplifying cells. Her work has revealed how these cells function as key communicators between stem cells and their niche, coordinating tissue production and regeneration. She discovered that hair follicle transit-amplifying cells secrete Sonic Hedgehog to promote dermal adipocyte precursors to make more adipocytes, enabling coordinated tissue growth during regeneration. Her research has important implications for understanding chemotherapy side effects and developing regenerative therapies. Dr. Hsu's publications demonstrate a consistent focus on stem cell niches and tissue regeneration, with increasing exploration of stress responses, metabolic regulation of stem cells, and neuro-dermal interactions in recent years. She has pioneered approaches to studying cell-cell communication in complex tissue environments, moving from basic developmental biology toward translational applications. Pew Biomedical Scholars Award Smith Family Award for Excellence in Biomedical Research Basil O'Connor Starter Scholar Award Smith Family Foundation Odyssey Award American Cancer Society Research Scholar Award Harvard's Roslyn Abramson Award for excellence and sensitivity in undergraduate teaching Dr. Hsu is an active mentor who emphasizes finding compatible team members with an adventurous spirit. She serves as associate director of the Developmental and Regenerative Biology (DRB) program in the Biological and Biomedical Sciences (BBS) PhD program and participates in multiple PhD programs across Harvard. Her teaching includes courses such as 'From Cells to Tissues, in Sickness and in Health' and 'Critical Analysis and Experimental Approaches in Developmental Biology,' where she emphasizes primary literature and hands-on laboratory experiences. The Hsu Laboratory, established in 2014, has grown from an initially empty space into a thriving research environment. Dr. Hsu emphasizes that the first group of lab members set the tone for the lab culture and helped her become a better mentor. The lab takes a multidisciplinary approach, combining genetic, molecular, and imaging techniques to study the mammalian skin system with its diverse cell types and multiple populations of somatic stem cells.
Valerie Tornini is an Assistant Professor at the Department of Integrative Biology and Physiology and the Institute for Society and Genetics within the College of Letters and Science at the University of California, Los Angeles (UCLA). Her research bridges fundamental biological mechanisms with ethical frameworks to address developmental and regenerative biology. Education: Not explicitly stated in the text. Research Interests Dr. Tornini focuses on understanding molecular mechanisms governing cell identity and chromatin regulation in vertebrate development, particularly neural systems. Her work explores micropeptides encoded by long non-coding RNAs and their role in neurodevelopment , regeneration , and evolutionary innovation . She also investigates bioethical implications of biomedical research and advocates for diversity, equity, and inclusion in science. Publication Trends Her recent publications emphasize zebrafish models to study organ regeneration (heart, bone, fins), micropeptide functions , and genetic networks . Key themes include chromatin accessibility , cell proliferation dynamics , and ethical dimensions of translational research. Labs & Collaborations She leads the Tornini Lab at UCLA, collaborating extensively with researchers like AJ Giraldez and KD Poss . Her team utilizes genome engineering , single-cell technologies , and confocal imaging to decode gene regulatory logic in development.
Steven C. Cramer, MD, is a Professor of Neurology at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). He holds the Susan and David Wilstein Endowed Chair in Rehabilitation Medicine and serves as Medical Director of Research at the California Rehabilitation Institute. Dr. Cramer is Co-Principal Investigator for the NIH StrokeNet clinical trials network and holds editorial roles at Neurorehabilitation and Neural Repair and Stroke . His research specializes in neural repair following stroke, employing innovative approaches including robotics, cellular therapies, brain stimulation, and telehealth interventions. Key focus areas include: Developing biomarkers for personalized stroke rehabilitation Translational research on neuroplasticity and motor recovery Clinical trials for novel neurorehabilitation technologies His publications predominantly explore neuroimaging biomarkers, vagus nerve stimulation, and rehabilitation efficacy, with consistent emphasis on translating basic neuroscience into clinical applications. Recent works demonstrate increasing focus on AI-driven rehabilitation and precision medicine approaches. Awards & Honors: Barbro B. Johansson Award in Stroke Recovery (2018) American Heart Association Stroke Rehabilitation Award (2017) Susan and David Wilstein Endowed Chair (2020) He leads multiple NIH-funded grants including R01HD095457 (brain-computer interfaces) and U01NS120910 (stroke recovery biomarkers), focusing on large-scale clinical validation. Dr. Cramer directs the UCLA Neural Repair Laboratory, collaborating internationally on neurorecovery consortia like ENIGMA Stroke Recovery.
